REG - Poolbeg Pharma PLC - POLB001 Data to be Presented at ASH Annual Meeting

Poolbeg PharmaAnnouncement

03/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231103:nRSC2623Sa&default-theme=true

RNS Number : 2623S  Poolbeg Pharma PLC  03 November 2023

Poolbeg Pharma plc

 

POLB 001 Data to be Presented at American Society of Hematology Annual
Meeting

 

Potential to address cancer treatment related Cytokine Release Syndrome

 

3 November 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company targeting diseases with a high unmet medical need,
announces that an abstract detailing POLB 001's promise as a potential
treatment for Cytokine Release Syndrome associated with cancer immunotherapies
has been accepted for presentation at 65th American Society of Hematology
('ASH') Annual Meeting and Exposition, to be held 9-12 December 2023 in San
Diego, California.

 

The ASH Annual Meeting and Exposition is recognised as the world's premier
conference focussing on haematological malignancies (blood cancers) and brings
together over 25,000 industry and academic attendees each year to share the
latest scientific discoveries and advances in clinical care.

 

Poolbeg's poster presentation will provide insight into the results obtained
from the POLB 001 LPS human challenge trial, highlighting its potential use in
the treatment of Cytokine Release Syndrome (CRS) associated with severe
influenza and cancer immunotherapies. Mild to moderate cases of CRS require
hospitalisation and can impact the ability to deliver the cancer
immunotherapies, severe cases of CRS can become life-threatening and may
require intensive care, and in rare cases cause mortality. An effective
therapy for CRS associated with cancer immunotherapies has the potential to
make these treatments more tolerable for individual patients to enable them to
best benefit from their treatment and to make cancer immunotherapies more
widely accessible.

 

Title: POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential
to Prevent Cytokine Release Syndrome (CRS)

Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational
Therapies: Poster I

Session Date: Saturday, December 9, 2023

Presentation Time: 5:30 PM - 7:30 PM

Presenter: Dr Emma Searle, Consultant Hematologist and Honorary Senior
Lecturer at University of Manchester

Location: San Diego Convention Center, Halls G-H

 

Dr Emma Searle, Consultant Hematologist and Honorary Senior Lecturer at
University of Manchester, said: "Having this abstract accepted at ASH
represents a strong validation of POLB 001's potential in addressing CRS in
oncology. Cytokine Release Syndrome is highly prevalent among patients
receiving immunotherapy for haematological malignancies. The positive data
from the LPS challenge trial has highlighted that oral treatment of POLB 001
holds great promise in tackling this issue; potentially leading to improved
patient outcomes, reduced strain on healthcare systems while making these
treatments more accessible to a broader patient population."

If you would like to meet with Poolbeg Pharma to discuss POLB 001, get in
touch: partnering@poolbegpharma.com (mailto:partnering@poolbegpharma.com)

Investor Meet Company Presentation

Poolbeg will be hosting a meeting for investors and analysts on the POLB 001
Oncology Programme on Monday 6 November 2023 at 2:00pm - 3:30pm GMT via
the Investor Meet Company platform
(https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor) .
 

The presentation is open to all existing and potential shareholders. Questions
can be submitted in advance via your Investor Meet Company dashboard up
until 9am the day before the meeting or at any time during the live
presentation.

 

Investors can sign up to Investor Meet for free and add Poolbeg Pharma
plc to their company dashboard via:

https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
(https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor)

 

- Ends -

 

Enquiries

 Poolbeg Pharma Plc                                                    +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                  +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                               +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                      +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg
Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
Pharma also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, leading to faster development and greater
commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg Pharma's
existing pipeline, the Company is progressing programmes in oncology and
metabolic syndromes; adding disease areas with significant addressable
markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/) , an industry
leading infectious disease and human challenge trials business, Poolbeg Pharma
has access to knowledge, experience, and clinical data from over 20 years of
human challenge trials. The Company is using these insights to acquire new
assets as well as reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction in p38
MAP kinase driven cytokines in a clinical setting; a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is progressing two Artificial Intelligence (AI) Programmes to add
promising new assets to its pipeline as well as developing an Oral Vaccine
Programme and utilising its licensed Oral Delivery Platform to target
metabolic conditions.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESUPGCUGUPWPUP